Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghui Zhou

Showing results (101-110 of 143) with videos related to

Pageof 15
Sort By:
International Journal of Environmental Research and Public Health|August 12, 2022
Study on Emission Characteristics and Emission Reduction Effect for Construction Machinery under Actual Operating Conditions Using a Portable Emission Measurement System (Pems)Junhui Chen, Yuan Li, Zhongwei Meng, et al.
Clinical Drug Investigation|March 21, 2013
Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studiesYaowei Zhu, Qingmin Wang, Bart Frederick, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 16, 2016
Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approachM Leire Ruiz-Cerdá, Itziar Irurzun-Arana, Ignacio González-Garcia, et al.
Chemical Communications (Cambridge, England)|November 26, 2008
Ultrathin epitaxial superconducting niobium nitride films grown by a chemical solution techniqueGuifu Zou, Menka Jain, Honghui Zhou, et al.
Clinical Pharmacology and Therapeutics|September 30, 2023
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung CancerNahor Haddish-Berhane, Yaming Su, Alberto Russu, et al.
Annals of the New York Academy of Sciences|July 25, 2012
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an updateNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
Annals of the New York Academy of Sciences|March 26, 2011
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectivesNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
The AAPS Journal|June 25, 2013
Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshopJane R Kenny, Maggie M Liu, Andrew T Chow, et al.
European Journal of Clinical Pharmacology|August 13, 2016
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasisYanli Zhuang, Cesar Calderon, Stanley J Marciniak, et al.
Inflammatory Bowel Diseases|November 7, 2013
Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 studyOmoniyi J Adedokun, Zhenhua Xu, Lakshmi Padgett, et al.
Pageof 15

Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
International Journal of Environmental Research and Public Health|August 12, 2022
Study on Emission Characteristics and Emission Reduction Effect for Construction Machinery under Actual Operating Conditions Using a Portable Emission Measurement System (Pems)Junhui Chen, Yuan Li, Zhongwei Meng, et al.
Clinical Drug Investigation|March 21, 2013
Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studiesYaowei Zhu, Qingmin Wang, Bart Frederick, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 16, 2016
Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approachM Leire Ruiz-Cerdá, Itziar Irurzun-Arana, Ignacio González-Garcia, et al.
Chemical Communications (Cambridge, England)|November 26, 2008
Ultrathin epitaxial superconducting niobium nitride films grown by a chemical solution techniqueGuifu Zou, Menka Jain, Honghui Zhou, et al.
Clinical Pharmacology and Therapeutics|September 30, 2023
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung CancerNahor Haddish-Berhane, Yaming Su, Alberto Russu, et al.
Annals of the New York Academy of Sciences|July 25, 2012
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an updateNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
Annals of the New York Academy of Sciences|March 26, 2011
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectivesNewman Yeilding, Philippe Szapary, Carrie Brodmerkel, et al.
The AAPS Journal|June 25, 2013
Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshopJane R Kenny, Maggie M Liu, Andrew T Chow, et al.
European Journal of Clinical Pharmacology|August 13, 2016
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasisYanli Zhuang, Cesar Calderon, Stanley J Marciniak, et al.
Inflammatory Bowel Diseases|November 7, 2013
Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 studyOmoniyi J Adedokun, Zhenhua Xu, Lakshmi Padgett, et al.
Pageof 15